Vimarsana
Biggest News Aggregation in the World

Page 8 - Crossover Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Crossover Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Crossover Management Today - Breaking & Trending Today

Q2 2023 Earnings Forecast for Allakos Inc. Issued By William Blair (NASDAQ:ALLK) - Vimarsana News

Q2 2023 Earnings Forecast for Allakos Inc. Issued By William Blair (NASDAQ:ALLK)

Allakos Inc. (NASDAQ:ALLK – Get Rating) – Equities researchers at William Blair lifted their Q2 2023 earnings per share estimates for shares of Allakos in a note issued to investors on Wednesday, May 10th. William Blair analyst T. Lugo now expects that the company will post earnings per share of ($0.51) for the quarter, up […]

Tyra Biosciences (NASDAQ:TYRA) Trading 21.5% Higher - Vimarsana News

Tyra Biosciences (NASDAQ:TYRA) Trading 21.5% Higher

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating)’s stock price traded up 21.5% during trading on Thursday . The company traded as high as $14.57 and last traded at $14.57. 5,977 shares traded hands during mid-day trading, a decline of 87% from the average session volume of 46,189 shares. The stock had previously closed at $11.99. […]

Source: wkrb13.com
Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells 3,800 Shares of Stock - Vimarsana News

Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) COO Sells 3,800 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Rating) COO Daniel Bensen sold 3,800 shares of Tyra Biosciences stock in a transaction dated Wednesday, March 22nd. The shares were sold at an average price of $16.00, for a total value of $60,800.00. Following the sale, the chief operating officer now owns 527,981 shares of the company’s stock, […]

Source: wkrb13.com
FY2022 Earnings Forecast for CymaBay Therapeutics, Inc. Issued By Oppenheimer (NASDAQ:CBAY) - Vimarsana News

FY2022 Earnings Forecast for CymaBay Therapeutics, Inc. Issued By Oppenheimer (NASDAQ:CBAY)

CymaBay Therapeutics, Inc. (NASDAQ:CBAY – Get Rating) – Research analysts at Oppenheimer increased their FY2022 earnings estimates for CymaBay Therapeutics in a research report issued to clients and investors on Sunday, August 14th. Oppenheimer analyst J. Olson now anticipates that the biopharmaceutical company will post earnings of ($1.36) per share for the year, up from […]

Alpine Immune Sciences (NASDAQ:ALPN) Stock Price Crosses Above Two Hundred Day Moving Average of $8.46 - Vimarsana News

Alpine Immune Sciences (NASDAQ:ALPN) Stock Price Crosses Above Two Hundred Day Moving Average of $8.46

Alpine Immune Sciences, Inc. (NASDAQ:ALPN – Get Rating)’s stock price crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $8.46 and traded as high as $8.94. Alpine Immune Sciences shares last traded at $8.80, with a volume of 60,111 shares changing hands. Analyst Upgrades and […]